This is a multi-center, randomized, open-label, multi-center, randomized controlled study of 80 Parkinson's disease patients with gait and balance disorders in which 40 patients will be treated with serious games, in addition to their usual care, for 12 months and 40 patients will be treated with their usual care during this period. This study will be conducted in 4 centers, all of which are expert in the management of these patients. After randomization, each patient in the "Intervention-Rehabilitation through Toap Run" group will have to complete 2 to 3 sessions per week at home with the serious game "TOAP RUN" using the Kinect® system for 1 year.
This is a multi-center, randomized, open-label, multi-center, randomized controlled study of 80 Parkinson's disease patients with gait and balance disorders in which 40 patients will be treated with serious games, in addition to their usual care, for 12 months and 40 patients will be treated with their usual care during this period. This study will be conducted in 4 centers, all of which are expert in the management of these patients. After randomization, each patient in the "Intervention-Rehabilitation through Toap Run" group will have to complete 2 to 3 sessions per week at home with the serious game "TOAP RUN" using the Kinect® system for 1 year. The primary endpoint is a medical-economic endpoint: the difference in incremental cost-utility ratio at 12 months between the 2 groups of patients. Costs will be assessed at inclusion, at the end of 6 and 12 months. Secondary endpoints include clinical and neurophysiological assessments, focusing on gait and balance disorders, as well as cognition and emotional state. An imaging study for patients included in the Paris-ICM center is also planned to study the effects of serious game rehabilitation on brain function. Patients in both groups will be free to use SG at the end of the intervention.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Enrollment
80
usual re-education treatment by their physiotherapist
Chu Bordeaux
Bordeaux, France
RECRUITINGChu Lille
Lille, France
RECRUITINGGh Pitie Salpetriere
Paris, France
RECRUITINGRouen University Hospital
Rouen, France
RECRUITINGThe incremental cost-utility ratio at 12 months for the management of patients with Parkinson's disease using therapeutic games
The result criterion is the additional cost in euros of a QALY gained. The QALY will be calculated from the utilities derived from the EuroQuality scale of life-5 dimensions EQ5D-3L.
Time frame: at 12 months for the management of patients with Parkinson's disease using therapeutic games
The frequency of falls
The frequency of falls will be measured using item 12 of the Freezing of gait questionnaire (FOG-Q), with falls being absent (score=0), very rare (about 1/year, score=1), rare (about 1/ month, score=2), frequent (about 1/week, score=3) or very frequent (every day or several falls per day, score=4).
Time frame: Through study completion, an average of 24 months
The incremental cost-effectiveness ratio of Toap Run therapeutic gambling management compared to usual management.
The outcome criterion will be measured by the number of days of hospitalization at 12 and 24 months.
Time frame: Through study completion, an average of 24 months
Cost-effectiveness ratio of falls prevention
For the cost-effectiveness ratio of falls prevention, the clinical outcome criterion will be measured by the number of falls at 12 and 24 months.
Time frame: Through study completion, an average of 24 months
Criterion for the cost-utility ratio
The criterion for the cost-utility ratio at 24 months will be the QALY calculated from the utilities derived from the EuroQuality scale of life-5 dimensions EQ5D-3L.
Time frame: Through study completion, an average of 24 months
The budgetary impact of Toap Run
The budgetary impact of Toap Run in the management of Parkinson's patients will be measured by the resources directly consumed using the SNIIRAM/SNDS database (order of March 22, 2017 of the Public Health Code).
Time frame: Through study completion, an average of 24 months
Incidence of treatment on Patients' quality of life
Patients' quality of life will be assessed using the PDQ-39 scale, which is specific to Parkinson's disease.
Time frame: Through study completion, an average of 24 months
Incidence of treatment on Motor skills
Motor skills (walking and balance) will be assessed using clinically validated scales (UPDRS, Gait and Balance Scale, Freezing-of-gait questionnaire, Fear of falling)
Time frame: Through study completion, an average of 24 months
Incidence of treatment on Neurological motor skills
Neurological motor skills will be assessed using a neurophysiological evaluation (VICON® System).
Time frame: Through study completion, an average of 24 months
Overall functioning
Overall functioning will be assessed by the Global Functioning Scale (GFS).
Time frame: Through study completion, an average of 24 months
Evaluation of usability and feasibility of SGs
The usability and feasibility of SGs will be assessed through by patients' usability and feasability questionnaire.
Time frame: Through study completion, an average of 24 months
Mood and anxiety
Mood and anxiety will be assessed with the Hospital Anxiety Depression scale (HAD).
Time frame: Through study completion, an average of 24 months
Emotional state
Emotional state will be assessed with the Positive Affect Negative Affect Scale (PANAS).
Time frame: Through study completion, an average of 24 months
The level of physical activity
The level of physical activity evaluated with the International Physical Activity Questionnaire (IPAQ).
Time frame: Through study completion, an average of 24 months
Patient and caregiver satisfaction
Patient and caregiver satisfaction will be assessed through a satisfaction survey.
Time frame: Through study completion, an average of 24 months
Physician user satisfaction
Physician user satisfaction will be assessed through a satisfaction survey.
Time frame: Through study completion, an average of 24 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.